A phase 1, first-in-human study of IK-930, an oral TEAD inhibitor targeting the Hippo pathway in subjects with advanced solid tumors.
Anthony W. Tolcher(South Texas Accelerated Research Therapeutics), Sergio Santillana, Trupti Lingaraj, Karim Malek(ImmunoGen (United States)), Laura Victor, Katherine Kacena, Meredith McKean(Sarah Cannon), Marta Sánchez-Martín, Nehal J. Lakhani(South Texas Accelerated Research Therapeutics)
Cited by 49
Related Papers
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
|The Lancet|2024|729
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis
|The Lancet Oncology|2018|658
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
|Journal of Clinical Oncology|2019|590